ClinicalTrials.gg
CompletedNCT06059326Updated Sep 28, 2023

Multiple-dose Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of HSK7653 in T2DM

A Phase 2 interventional study of HSK7653 10 mg and HSK7653 25 mg in Type 2 Diabetes Mellitus, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-09-28.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 8 months after the study started (first participant enrolled Jan 2019, registered Sep 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 909 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 228 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Enrollment
617th of 767
48 · median 199
Started
2019
with 51 others
Phase 2
61 of 909
14 open now
Registered
606th of 909
by date

Among the 909 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 617th largest by enrollment of the 767 interventional ones that give a count, is one of 52 that started in 2019, is one of 61 in phase 2, and was the 606th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 909 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 909 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

To evaluate the safety, tolerability and pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of HSK7653 tablets in Type 2 Diabetes Mellitus Patients.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 and Age ≤70 years
  • T2DM patients,
  • Control the blood glucose level only with diet and exercise in last 3 months;
  • ≥19 and BMI ≤ 35 kg/m2 (Body Mass Index)
  • ≥7.0% and HbA1c \<10.0%
  • FPG \<13.9 mmol/L

Exclusion criteria

Exclusion Criteria:

  • Non-type 2 diabetes mellitus: Type 1 diabetes mellitus, gestational diabetes history;
  • History of acute complications of diabetes (diabetic ketoacidosis, diabetic hyperglycemia hyperosmolar syndrome or lactic acidosis);
  • History of chronic complications of severe diabetes (retinal proliferative disease, severe diabetic neuropathy or intermittent claudication confirmed by fundus examination during screening);
  • Patients who used systemic within 3 months prior to screening had severe infections or major surgeries and transplants within 3 months;
  • Three or more episodes of hypoglycemia occurred in the six months prior to screening;
  • History of hyperthyroidism within 6 months before screening;
  • Severe cardiovascular disease. ;
  • Medical conditions that may significantly affect drug absorption, distribution, metabolism, and excretion within 2 weeks prior to screening;
  • Liver function tests abnormal;
  • Moderate or severe renal impairment;
  • Medical history or clinical evidence of pancreatic injury or pancreatitis, or abnormalities in lipase and amylase judged by investigators to be ;
  • Patients with a history of hypertension who regularly take antihypertensive therapy for over 4 weeks still have poor control, SBP > 160 mmHg and (or) DBP > 100 mmHg;
  • Patients with uncontrolled hyperlipidemia.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    HSK7653 10 mg

    Drug: HSK7653 10 mg

  • Experimental
    HSK7653 25 mg

    Drug: HSK7653 25 mg

  • Experimental
    HSK7653 50 mg

    Drug: HSK7653 50 mg

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Assessment by adverse event monitoring, 12 lead ECGs, vital signs and laboratory measurements.

    Time frame: From baseline to up to 2 weeks after last dose for a total of approximately 14 weeks

Secondary outcomes

  1. Peak plasma concentration (Cmax) of HSK7653

    Cmax of HSK7653 after first dose and multi-dose administration

    Time frame: Day 1 to Day 43

  2. Area under the plasma concentration versus time curve (AUC) of HSK7653

    AUC of HSK7653 after first dose and multi-dose administration

    Time frame: Day 1 to Day 43

  3. Half-life (t1/2) of HSK7653

    T1/2 of HSK7653 after single-dose and multi-dose administration

    Time frame: Day 1 to Day 43

  4. Change from baseline in dipeptidyl peptidase-IV (DPP-4) inhibition rate

    Change from baseline in dipeptidyl peptidase-IV (DPP-4) inhibition rate after single-dose and multi-dose administration of HSK7653

    Time frame: Day 1 to Day 84

  5. Change from baseline in GLP-1

    Change from baseline in GLP-1 after single-dose and multi-dose administration of HSK7653

    Time frame: Day 1 to Day 84

  6. Change from baseline of fasting plasma glucose

    Change from baseline in fasting plasma glucose after multi-dose administration of HSK7653

    Time frame: Day 1 to Day 84

  7. Change from baseline of HbA1c

    Change from baseline in HbA1c after multi-dose administration of HSK7653

    Time frame: Day 1 to Day 84

07

Study locations

1 site
  • Peking university people's hospital
    Beijing, Beijing 100044, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Nov 2019, 9 months.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 9 months is below that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2023
First posted
Sep 28, 2023
StartActual
Jan 22, 2019
Primary completionActual
Nov 5, 2019
CompletionActual
Nov 5, 2019
Last update
Sep 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06059326
Responsible party
Sponsor
First posted
Sep 28, 2023
Start date
Jan 22, 2019
Primary completion
Nov 5, 2019
Completion
Nov 5, 2019
Last update
Sep 28, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HSK7653

Start the discussion